Audentes’ former CEO launches new biotech, with $155M for hives and inflammation
Former Audentes CEO Natalie Holles is ready to debut her next project, and it’s one that’s music to her ears.
Third Harmonic Bio launched Wednesday morning with a $105 million Series B and a plan to change the game in chronic urticaria, a condition with several causes that causes severe and debilitating hives. Holles, who joined last August, said Third Harmonic has a lead program already in the clinic and expects to launch a Phase Ib study later this year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.